Healthcare

The company's intravenous-infused psilocin candidate, TRP-8803, was studied in patients with treatment-resistant Binge Eating Disorder — a neuropsychiatric condition with limited approved pharmacological treatmentOptionsand significant unmet medical need. The results from the Phase 2 study showed 100% of patients achieving clinically meaningful improvement, with …

The company ended Q1 FY27 with $65.1 million in cash and no borrowings, after recording a net operating cash outflow of $10.4 million for the three months to 30 September 2026. That compares with an outflow of $8.3 million in Q4 FY26 and $5.7 …

The speed of that transition — from signed agreements to dispensed prescriptions — is a meaningful operational data point for a pharmaceutical company navigating the Section 503A compounding pathway in the US market. It demonstrates that the commercial infrastructure assembled across the quarter functioned …

The commencement of dosing advances NTI164 into pivotal Phase 3 clinical development, which is the final and most significant trial stage before regulatory submission. The study is a national, multi-centre, randomised, double-blind, placebo-controlled design — the gold standard for pharmaceutical clinical evidence — evaluating …

PYC Therapeutics Limited is a Perth-based biotechnology company, listed on the ASX since 30 March 2005 and classified by the ASX in Health Care. Its shares are ordinary shares, and the ASX lists it in the S&P/ASX 300, All Ordinaries and Small Ordinaries indices.

The application rests on 36-month data from uniQure's Phase I/II clinical studies of ifezuntirgene inilparvovec, analyzed against a propensity score-matched external control cohort drawn from the Enroll-HD natural history database — one of the most comprehensive longitudinal registries for Huntington's disease patients worldwide. The …

RAD101, a fatty acid synthase-targeting imaging agent labeled with Fluorine-18, has cleared its most significant near-term regulatory hurdle. Following a productive end-of-Phase 2 meeting with the U.S. Food and Drug Administration, the company is now preparing to initiate a pivotal, multi-center global Phase 3 …